Table 1.

Human infiltrating lobular breast cancer cell models

			Protein expression				Mutational status			Molecular subtype
	Tumor origin	Tissue	Ecad	ER	PR	ERBB2	CDH1	TP53	CTNNA1		References
Cell lines
MDA-MB-134	Unknown (ILC?)	A	Neg	Pos	Neg	Neg	muta	wt/mutd	wt	lum	[25,30,34-40,45]
MDA-MB-330	ILC	P	Pos	Neg	Neg	Pos	wt	mute	muti	ErbB2-pos	[26,46]
MA-11	Mixed ITC/ILC	BM	Pos	Neg	Neg	Neg	NA	NA	NA	NA	[27]
SUM-44PE	Unknown (ILC?)	P	Neg	Pos	Pos	Neg	mutb	mutf	wt	lum	[28,33,36-38]
HCC-2185	ILC	P	NA	Neg	Neg	Pos	NA	NA	NA	lum	[24,29]
IPH-926	ILC	A	Neg	Neg	Neg	Neg	mutc	mutg	wt	lum	[30,33,41-43,70]
BCK-4	Unknown (muc-ILC?)	P	Neg	Pos	Pos	Neg	na	na	NA	NA	[31]
Xenograft tumors
HBCX-7	ILC	PT	NA	Neg	Neg	Neg	NA	wt	NA	NA	[48]
HBCX-19	ILC	PT	NA	Neg	Neg	Neg	NA	muth	NA	NA	[48]
HBCX-36	ILC	PT	NA	Pos	Pos	Pos	NA	NA	NA	NA	[49]
HCI-005	Mixed ILC/IDC	P	Pos	Pos	Pos	Pos	NA	NA	NA	NA	[47]
HCI-013	ILC	P	Neg	Pos	NA	NA	NA	NA	NA	NA	[36]

All information compiled from the literature; molecular subtype determined by microarray expression profiling in different studies. A, malignant ascites; BM, bone metastasis; Ecad, E-cadherin; ER, estrogen receptor; IDC, infiltrating ductal breast cancer; ILC, infiltrating lobular cancer; ITC, infiltrating tubular cancer; lum, luminal; muc-ILC, ILC with extracellular mucin; mut, mutated; NA, not assessed; neg, negative; P, malignant pleural effusion; pos, positive; PR, progesterone receptor; PT, primary breast tumor; wt, wild-type. ^ac.688del145; p.L230EfsX4. ^bc.1269delT; p.F423LfsX8. ^cc.241ins4;p.V82fsX93. ^dc.853G > A; p.E285K. Different mutational status in different studies; possibly a TP53-mutated subclone exists. ^ec.659C > T; p.Y220C. ^fc.82_84delinsCA; pE28fsX16. ^gc.853G > A; p.E285K. ^hSequence unknown. ⁱc.1322C > G; p.S441X.